Physician profile

Alexandre Benjo

Interventional Cardiology · Tucson, AZ

NPI 1164606448

$15,387.77

in general payments reported to CMS, 2019-2025

39 companies · $2,382 in 2025

The $2,382 reported for 2025 was more than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$6,982.80
Travel and Lodging$60.69

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Abbott Laboratories $3,577.91 2019-2025 Cardiomems, Aveir, Emboshield Nav6
Cvrx, INC. $1,840.10 2022-2025 Barostim Neo System
Medtronic, INC. $1,678.35 2021-2025 Venaseal, Micra, Evera Mri Xt Dr Surescan
Medtronic Vascular, INC. $1,286.01 2019-2020
Janssen Pharmaceuticals, INC $1,203.50 2019-2023 Xarelto
Novartis Pharmaceuticals Corporation $972.13 2019-2025
Impulse Dynamics (USA) INC. $624.15 2022-2025 Optimizer, Optimizer
E.R. Squibb & Sons, L.L.C. $411.26 2019-2025 Camzyos, Eliquis
Kestra Medical Technology Services, INC. $396.98 2024-2025 Assure Wcd
Abiomed $394.62 2020-2025 Impella
Zoll Services LLC (A/K/A Zoll Lifecor Corp) $369.02 2019-2025 Lifevest
Merck Sharp & Dohme LLC $345.10 2021-2025 Winrevair, Verquvo
Biotronik INC. $316.72 2019-2020
Edwards Lifesciences Corporation $315.77 2024-2025 Sapien 3 Ultra Resilia
Actelion Pharmaceuticals US, INC. $173.55 2020-2025 Opsumit, Uptravi
Show all 39 companies
CompanyGeneral paymentsYearsTop products
Biosense Webster, INC. $148.59 2024-2025 Carto 3
Elutia, INC. $137.40 2025 Ecm Patch,Pouch
Cardiva Medical, INC. $124.54 2022-2023 Cardiva Vascade 6/7f Vcs
Angiodynamics, INC. $112.45 2025 Auryon Laser System 100-120 Vac
Pfizer INC. $111.32 2019
Astrazeneca Pharmaceuticals LP $88.38 2019-2023 Farxiga
Boston Scientific Corporation $81.36 2019-2025 Varithena Administration Pack
Bard Peripheral Vascular, INC. $81.04 2021
Amarin Pharma, INC. $69.75 2020-2021
Inari Medical, INC. $68.27 2021-2023 Ct Thrombectomy System Kit, Flowtriever Catheter, S
Lundbeck LLC $65.79 2019-2020
Amgen INC. $61.20 2020-2023 Repatha
Boehringer Ingelheim Pharmaceuticals, INC. $52.07 2022-2023 Jardiance
Cardiovascular Systems INC. $52.00 2020-2021
Novo Nordisk INC $38.52 2023 Ozempic
Chiesi USA, INC. $36.73 2020-2021
Kiniksa Pharmaceuticals International, Plc $24.26 2024 Arcalyst
Atricure, INC. $23.92 2022
Vital Connect, INC $22.14 2023 Vitalpatch Rtm
Bayer Healthcare Pharmaceuticals INC. $19.44 2024
Itamar Medical INC $18.02 2022
Kiniksa Pharmaceuticals, LTD. $17.96 2023 Arcalyst
Bardy Diagnostics, INC. $15.00 2021
Regeneron Healthcare Solutions, INC. $12.45 2019

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Alexandre Benjo

$15,387.77

in general payments reported 2019-2025

Years
2019-2025
Top company
Abbott Laboratories
Context
The $2,382 reported for 2025 was more than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).

https://glasscript.com/doctor/1193471/alexandre-benjo

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.